Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    

Investigational Vaccine to be Tested Against COVID-19 Variant


Vanderbilt University Medical Center (VUMC) is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.

The multicenter trial, which began this week <March 31>, is evaluating the safety and immunogenicity of the mRNA-1273.351vaccine developed by the Cambridge, Massachusetts-based biotechnology company ModernaTX, Inc. The trial is led and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Approximately 210 healthy adult volunteers at VUMC and three other clinical research sites in the NIAID-funded Infectious Diseases Clinical Research Consortium (IDCRC) will receive the vaccine. Lisa A. Jackson, MD, MPH, senior investigator at the Kaiser Permanente Washington Health Research Institute in Seattle, is the study's principal investigator.

"There is an 'arms race' right now between the vaccine and these variants," said Buddy Creech, MD, MPH, director of the Vanderbilt Vaccine Research Program who will lead the VUMC trial. "We need to put maximum pressure on the virus as fast as we can so that those variants can't take hold."

On March 4 the Tennessee Department of Health confirmed the state's first case of the B.1.351 variant, which appears to spread more readily than the original strain of the COVID-19 virus, SARS-CoV-2.

"Preliminary data show that the COVID-19 vaccines currently available in the United States should provide an adequate degree of protection against SARS-CoV-2 variants," NIAID Director Anthony S. Fauci, MD, said in a news release announcing the phase 1 trial.

"However, out of an abundance of caution, NIAID has continued its partnership with Moderna to evaluate this variant vaccine candidate should there be a need for an updated vaccine," Fauci said.

VUMC's participation in the phase 1 trial of the mRNA-1273.351 vaccine will involve healthy adults who have not previously been vaccinated against or infected by SARS-CoV-2, Creech said.

The volunteers will be randomly assigned to receive different combinations of Moderna vaccines made against the original and variant strains of SARS-CoV-2. The ability of each combination to trigger an immune response that can neutralize both strains will be assessed. Preliminary findings from the study are expected in May.

At this time, the research sites anticipate they will have an adequate number of volunteers for this study. For more information, visit and search for trial identifier NCT04785144.

Investigators from NIAID and Moderna co-developed the mRNA-1273 vaccine, currently one of three vaccines authorized by the U.S. Food and Drug Administration for emergency use for prevention of COVID-19 in adults 18 years old and older.

Creech led phase 3 testing at VUMC of the first Moderna vaccine and another COVID-19 vaccine developed by Janssen Biotech Inc., a pharmaceutical company of Johnson & Johnson. Last month the Johnson & Johnson vaccine became the third COVID-19 vaccine authorized for emergency use.

Creech is principal investigator of the NIH-funded Vanderbilt Vaccine and Treatment Evaluation Unit (VTEU), which as part of the IDCRC works to develop and test vaccine and other therapies to combat infectious diseases.

The mRNA-1273.351 vaccine trial at VUMC is funded in whole or in part by the NIAID, U.S. Department of Health and Human Services and VTEU Cooperative Agreement/Grant number UM1AI148452.


Related Articles:

Recent Articles

Blackburn, Duckworth Lead Bipartisan Legislation to Improve Lives of People with Limb Loss

U.S. Senator Marsha Blackburn (R-Tenn.) introduced bicameral, bipartisan legislation along with Senator Tammy Duckworth (D-Ill.) to improve health outcomes for individuals living with limb loss or limb differences.

Read More

Method Proposed to Correct Misinterpretations of Long-Term Survival Rates for Immunotherapies

Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.

Read More

Blackburn, Durbin Introduce Legislation to Improve Rural Health Care

U.S. Senator Marsha Blackburn (R-Tenn.) along with Senators Dick Durbin (D-Ill.), Lisa Murkowski (R-Ala.), and Tina Smith (D-Minn.) introduced the bipartisan Rural America Health Corps Act. Representatives Cheri Bustos (D-Ill.) and David Kustoff (R-Tenn.) introduced companion legislation in the House of Representatives.

Read More

AHA Statement On Senate Passage Of Medicare Sequester Relief Legislation

Read More

Crucial Behavioral Health Bill Introduced

Reps. Dan Kildee (D-Mich.) and Brad Wenstrup (R-Ohio) introduced their bipartisan bill, the Rural Behavioral Health Access Act.

Read More

New Analysis Shows Continued Negative Impact Of COVID-19 On Hospital & Health System Financial Health In 2021

A new analysis prepared by Kaufman, Hall & Associates, LLC and released by the American Hospital Association (AHA) highlights the ongoing consequences of the COVID-19 pandemic on the financial stability of hospitals and health systems, threatening their ability to continue to provide essential services to their patients and communities.

Read More

NAACOS Asks HHS Secretary Xavier Becerra to Grow Medicare ACO Programs

Letter Recommends National Goal to Have a Majority of Traditional Medicare Beneficiaries in an ACO by 2025

Read More

Luck of the Irish

Read More

Artificial Intelligence Calculates Suicide Attempt Risk

A machine learning algorithm that predicts suicide attempt recently underwent a prospective trial at the institution where it was developed, Vanderbilt University Medical Center.

Read More

Pre-term Births in Tennessee Decreased During Pandemic

Statewide stay-at-home orders put in place as Tennessee fought to control the spread of coronavirus last March were associated with a 14% lower rate of preterm birth, according to a research letter published today in JAMA Pediatrics.

Read More

Email Print



Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: